China Natural Investment Company Limited
中國天然投資有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8250)

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 30 JUNE 2013

CHARACTERISTICS OF THE GROWTH ENTERPRISE MARKET ("GEM") OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHANGE")

GEM has been positioned as a market designed to accommodate companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration. The greater risk profile and other characteristics of GEM mean that it is a market more suited to professional and other sophisticated investors.

Given the emerging nature of companies listed on GEM, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board of the Stock Exchange and no assurance is given that there will be a liquid market in the securities traded on GEM.

*This announcement, for which the directors (the "**Directors**") of China Natural Investment Company Limited (the "**Company**") collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM (the "**GEM Listing Rules**") for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

This announcement will remain on the "Latest Company Announcements" page of the GEM website at http://www.hkgem.com for at least seven days from the date of its publication and is available for reference on the website of the Company at http://www.chinanatural.com.hk.

FINANCIAL HIGHLIGHTS

For the year ended 30 June 2013:

- Revenue from continuing operations amounted to approximately HK$44,203,000 (2012: HK$51,252,000), representing a decrease of 13.75% as compared with that of the corresponding year in 2012.

- Profit attributable to owners of the Company amounted to approximately HK$11,683,000 (2012: loss of approximately HK$16,181,000). The significant improvement was mainly due to gains arising on (i) change in fair value of held-for-trading investments; (ii) share of profits in associates; and (iii) disposal of discontinued operation.

As at 30 June 2013:

- The Group had cash and cash equivalents of approximately HK$120,984,000 (2012: HK$32,847,000). Net current assets amounted to approximately HK$206,629,000 (2012: HK$103,314,000).

- Current ratio (defined as total current assets divided by total current liabilities) was approximately 34.72 times (2012: 12.54 times). Gearing ratio (expressed as the ratio of total liabilities over total assets) was approximately 0.01 (2012: 0.03).

The Board does not recommend the payment of final dividend.

FINANCIAL RESULTS

The board of Directors (the "Board") hereby announces the audited consolidated results of the Company and its subsidiaries (collectively referred to as the "Group") for the year ended 30 June 2013 (the "Year") together with the comparative figures for the year ended 30 June 2012 as follows:

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the year ended 30 June 2013

	Notes	Year ended 30 June 2013 HK$	Year ended 30 June 2012 HK$ (restated)
Continuing operations			
Revenue	4	**44,202,758**	51,252,055
Cost of sales and services provided		**(29,880,620)**	(31,711,747)
Gross profit		**14,322,138**	19,540,308
Investment and other income	6	**2,677,972**	1,525,585
Selling and distribution expenses		**(3,294,021)**	(6,888,529)
Administrative expenses		**(26,755,765)**	(29,167,733)
Other operating expenses		**(3,574,947)**	(5,304,117)
Gain/(loss) arising on change in fair value of held-for-trading investments		**2,594,400**	(5,286,457)
Gain on disposal of subsidiaries		**1,084**	727,801
Impairment losses recognised in respect of goodwill		**(5,200,000)**	(4,000,000)
Finance costs		**(4,279,952)**	–
Share of profits of associates		**11,880,819**	–
Loss before tax		**(11,628,272)**	(28,853,142)
Income tax credit/(expense)	7	**409,011**	(428,577)
Loss for the year from continuing operations	8	**(11,219,261)**	(29,281,719)
Discontinued operation			
Profit for the year from discontinued operation	9	**22,901,926**	13,100,446
Profit/(loss) for the year		**11,682,665**	(16,181,273)
Other comprehensive (expense)/income, net of income tax			
Items that will not be reclassified to profit or loss:			
Gain arising on revaluation of property transferred to investment property		**–**	221,726
Items that may reclassified subsequently to profit or loss:			
Exchange differences on translating foreign operations		**(228,693)**	–
Other comprehensive (expense)/income for the year, net of income tax		**(228,693)**	221,726

	Notes	Year ended 30 June 2013 HK$	Year ended 30 June 2012 HK$ (restated)
Total comprehensive income/(expense) for the year		**11,453,972**	(15,959,547)
Earnings/(loss) per share	*11*		
For continuing and discontinued operations			
Basic and diluted (HK cents per share)		**0.4**	(1.3)
For continuing operations			
Basic and diluted (HK cents per share)		**(0.4)**	(2.4)

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 30 June 2013

	Notes	As at 30 June 2013 HK$	As at 30 June 2012 HK$
Non-current assets			
Property, plant and equipment		**3,937,698**	5,420,227
Investment properties		**–**	183,300,000
Goodwill		**17,061,838**	22,261,838
Interests in associates		**245,014,755**	–
		266,014,291	210,982,065
Current assets			
Inventories		**4,990,720**	6,515,295
Trade and other receivables	*12*	**73,182,672**	46,807,972
Held-for-trading investments		**13,576,900**	25,906,100
Current tax assets		**23,100**	193,221
Cash and cash equivalents		**120,983,545**	32,846,867
		212,756,937	112,269,455
Current liabilities			
Trade and other payables	*13*	**6,127,526**	8,955,004
Net current assets		**206,629,411**	103,314,451
Total assets less current liabilities		**472,643,702**	314,296,516
Non-current liabilities			
Deferred tax liabilities		**33,140**	1,158,746
Net assets		**472,610,562**	313,137,770
Capital and reserves			
Share capital		**233,125,117**	83,125,117
Reserves		**239,485,445**	230,012,653
Total equity attributable to owners of the Company		**472,610,562**	313,137,770

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the year ended 30 June 2013

	Attributable to owners of the Company							
	Share capital HK$	Share premium HK$	Share options reserve HK$	Property revaluation reserve HK$	Foreign currency translation reserve HK$	Convertible notes reserve HK$	Accumulated losses HK$	Total HK$
Balance at 1 July 2011	55,416,745	296,335,047	837,295	–	–	–	(60,624,373)	291,964,714
Loss for the year	–	–	–	–	–	–	(16,181,273)	(16,181,273)
Other comprehensive income for the year	–	–	–	221,726	–	–	–	221,726
Total comprehensive expense for the year	–	–	–	221,726	–	–	(16,181,273)	(15,959,547)
Issue of new shares by way of open offer	27,708,372	11,083,349	–	–	–	–	–	38,791,721
Share issue expenses	–	(1,659,118)	–	–	–	–	–	(1,659,118)
Balance at 30 June 2012	83,125,117	305,759,278	837,295	221,726	–	–	(76,805,646)	313,137,770
Profit for the year	–	–	–	–	–	–	11,682,665	11,682,665
Other comprehensive expense for the year	–	–	–	(221,726)	(228,693)	–	221,726	(228,693)
Total comprehensive income for the year	–	–	–	(221,726)	(228,693)	–	11,904,391	11,453,972
Issue of new shares by way of placing	50,000,000	–	–	–	–	–	–	50,000,000
Share issue expenses	–	(1,928,690)	–	–	–	–	–	(1,928,690)
Lapse of share options granted under Right of First Refusal Agreement	–	–	(837,295)	–	–	–	837,295	–
Recognition of the equity component of convertible notes	–	–	–	–	–	44,581,533	–	44,581,533
Deferred tax liability on recognition of equity component of convertible notes	–	–	–	–	–	(7,954,284)	–	(7,954,284)
Conversion of convertible notes to ordinary shares	100,000,000	(52,490)	–	–	–	(43,875,341)	–	56,072,169
Release of deferred tax liability recognised on conversion of convertible notes	–	–	–	–	–	7,248,092	–	7,248,092
Balance at 30 June 2013	**233,125,117**	**303,778,098**	**–**	**–**	**(228,693)**	**–**	**(64,063,960)**	**472,610,562**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

1. GENERAL

The Company was incorporated in the Cayman Islands as an exempted company with limited liability under the Companies Law of the Cayman Islands, and its shares are listed on the GEM of the Stock Exchange.

The Company is an investment holding company. Its subsidiaries are principally engaged in the manufacturing and sale of pharmaceutical products, provision of advertising and public relations services and investment holding.

The consolidated financial statements are presented in Hong Kong dollars ("HK$"), which is the same as the functional currency of the Company. Each entity in the Group determines its own functional currency and items included in the financial statements of each entity are measured using that functional currency.

2. BASIS OF PREPARATION

The consolidated financial statements have been prepared on the historical cost basis except for investment properties and certain financial instruments that are measured at fair values, as explained in the accounting policies set out below.

The consolidated financial statements have been prepared in accordance with Hong Kong Financial Reporting Standards ("HKFRSs") issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA"). In addition, the consolidated financial statements include applicable disclosures required by the GEM Listing Rules and the Hong Kong Companies Ordinance.

3. APPLICATION OF NEW AND REVISED HONG KONG FINANCIAL REPORTING STANDARDS

The accounting policies and methods of computation used in these financial statements are the same as those followed in the preparation of the Group's annual financial statements for the year ended 30 June 2012, except for the following amendments to HKFRSs that the Group has applied for the first time in the current year and which have a material effect on the disclosures set out in these consolidated financial statements.

Amendments to HKAS 1 titled Presentation of Items of Other Comprehensive Income

The Group has applied for the first time the amendments to HKAS 1 *Presentation of Items of Other Comprehensive Income* in the current year. The amendments introduce new terminology for the statement of comprehensive income and income statement. Under the amendments to HKAS 1, the 'statement of comprehensive income' is renamed as the 'statement of profit or loss and other comprehensive income' and the 'income statement' is renamed as the 'statement of profit or loss'. The amendments to HKAS 1 retain the option to present profit or loss and other comprehensive income in either a single statement or in two separate but consecutive statements. However, the amendments to HKAS 1 require additional disclosures to be made in the other comprehensive income section such that items of other comprehensive income are grouped into two categories: (a) items that will not be reclassified subsequently to profit or loss and (b) items that may be reclassified subsequently to profit or loss when specific conditions are met. Income tax on items of other comprehensive income is required to be allocated on the same basis – the amendments do not change the option to present items of other comprehensive income either before tax or net of tax. The amendments have been applied retrospectively, and hence the presentation of items of other comprehensive income has been modified to reflect the changes. Other than the above mentioned presentation changes, the application of the amendments to HKAS 1 does not result in any impact on profit or loss, other comprehensive income and total comprehensive income.

New and revised HKFRSs in issue but not yet effective

The Group has not early applied the following new and revised HKFRSs that have been issued but are not yet effective:

HKFRSs (Amendments)	Annual Improvements to 2009 – 2011 Cycle[1]
HKFRS 1 (Amendments)	First-time adoption of HKFRS – Government Loans[1]
HKFRS 7 (Amendments)	Disclosures – Offsetting Financial Assets and Financial Liabilities[1]
HKFRS 9 and HKFRS 7 (Amendments)	Mandatory Effective Date of HKFRS 9 and Transition Disclosures[3]
HKFRS 10, HKFRS 11 and HKFRS 12 (Amendments)	Consolidated Financial Statements, Joint Arrangements and Disclosure of Interests in Other Entities: Transition Guidance[1]
HKFRS 10, HKFRS 12 and HKAS 27 (Amendments)	Investment Entities[2]
HKFRS 9	Financial Instruments[3]
HKFRS 10	Consolidated Financial Statements[1]
HKFRS 11	Joint Arrangements[1]
HKFRS 12	Disclosure of Interests in Other Entities[1]
HKFRS 13	Fair Value Measurement[1]
HKAS 32 (Amendments)	Offsetting Financial Assets and Financial Liabilities[2]
HKAS 36 (Amendments)	Recoverable Amount Disclosures for Non-Financial Assets[2]
HKAS 39 (Amendments)	Novation of Derivatives and Continuation of Hedge Accounting[2]
HKAS 19 (Revised 2011)	Employee Benefits[1]
HKAS 27 (Revised 2011)	Separate Financial Statements[1]
HKAS 28 (Revised 2011)	Investments in Associates and Joint Ventures[1]
HK (IFRIC) – Int 20	Stripping Costs in the Production Phase of a Surface Mine[1]
HK (IFRIC) – Int 21	Levies[3]

[1] Effective for annual periods beginning on or after 1 January 2013.
[2] Effective for annual periods beginning on or after 1 January 2014.
[3] Effective for annual periods beginning on or after 1 January 2015.

4. REVENUE

An analysis of the Group's revenue for the year from continuing operations is as follows:

	Year ended 30 June 2013 ***HK$***	Year ended 30 June 2012 *HK$* (restated)
Provision of diagnostic testing and healthcare services, manufacturing and sale of pharmaceutical products	**22,350,895**	25,222,535
Provision of advertising and public relations services	**21,851,863**	26,029,520
	44,202,758	51,252,055

5. SEGMENT INFORMATION

Information reported to the directors of the Company, being the chief operating decision maker, for the purposes of resource allocation and assessment of segment performance focuses on the types of goods or services delivered or provided. No operating segments identified by the chief operating decision maker have been aggregated in arriving at the reportable segments of the Group.

Specifically, the Group's reportable and operating segments under HKFRS 8 are as follows:

- Healthcare and pharmaceutical – Provision of diagnostic testing and healthcare services, manufacturing and sale of pharmaceutical products

- Advertising and public relations – Provision of advertising and public relations services

The property investment operation was discontinued in the current year. The following segment information reported does not include any amounts for the discontinued operation, which are described in more detail in note 9 of this announcement.

Segment revenue and results

The following is an analysis of the Group's revenue and results from continuing operations by reportable segment.

	Segment revenue		**Segment result**	
	Year ended 30 June 2013	Year ended 30 June 2012	**Year ended 30 June 2013**	Year ended 30 June 2012
	HK$	*HK$* (restated)	***HK$***	*HK$* (restated)
Healthcare and pharmaceutical	**22,350,895**	25,222,535	**(10,795,710)**	(13,367,660)
Advertising and public relations	**21,851,863**	26,029,520	**(6,107,138)**	(4,644,663)
Total for continuing operations	**44,202,758**	51,252,055	**(16,902,848)**	(18,012,323)
Share of profits of associates			**11,880,819**	–
Investment and other income			**2,677,972**	1,525,585
Gain/(loss) arising on change in fair value of held-for-trading investments			**2,594,400**	(5,286,457)
Gain on disposal of subsidiaries			**1,084**	727,801
Central administrative costs			**(11,879,699)**	(7,807,748)
Loss before tax (continuing operations)			**(11,628,272)**	(28,853,142)

Segment revenue reported above represents revenue generated from external customers. There were no inter-segment sales in the current year (2012: nil).

Segment loss represents the loss incurred by each segment without allocation of share of profits of associates, investment and other income, gain/(loss) arising on change in fair value of held-for-trading investments, gain on disposal of subsidiaries, central administrative costs and income tax credit/(expense). This is the measure reported to the chief operating decision maker for the purposes of resource allocation and assessment of segment performance.

Segment assets and liabilities

	As at 30 June 2013	As at 30 June 2012
	HK$	*HK$*
		(restated)
Segment assets		
Healthcare and pharmaceutical	**14,007,323**	17,262,515
Advertising and public relations	**23,318,135**	37,524,869
Total segment assets	**37,325,458**	54,787,384
Assets relating to property investment (now discontinued)	**–**	188,835,717
Unallocated	**441,445,770**	79,628,419
Consolidated assets	**478,771,228**	323,251,520
Segment liabilities		
Healthcare and pharmaceutical	**2,745,283**	4,425,775
Advertising and public relations	**1,208,176**	2,906,777
Total segment liabilities	**3,953,459**	7,332,552
Liabilities relating to property investment (now discontinued)	**–**	2,501,853
Unallocated	**2,207,207**	279,345
Consolidated liabilities	**6,160,666**	10,113,750

For the purposes of monitoring segment performance and allocating resources between segments:

- All assets are allocated to operating segments other than unallocated assets (mainly comprising interests in associates, held-for-trading investments and certain other receivables and cash and cash equivalents). Goodwill is allocated to segments on the basis same as 2012; and

- All liabilities are allocated to operating segments other than unallocated liabilities (mainly comprising deferred tax liabilities and certain other payables).

Other segment information

	Year ended 30 June 2013 *HK$*	Year ended 30 June 2012 *HK$* (restated)
Depreciation		
Healthcare and pharmaceutical	**1,037,745**	1,406,199
Advertising and public relations	**498,730**	557,838
Unallocated depreciation	**86,742**	191,460
Total	**1,623,217**	2,155,497
Additions to non-current assets		
Healthcare and pharmaceutical	**442,444**	682,582
Advertising and public relations	**2,402**	603,638
Unallocated non-current assets	**88,869**	997,688
Total	**533,715**	2,283,908
Impairment losses recognised in respect of goodwill		
Advertising and public relations	**5,200,000**	4,000,000

Geographical information

Substantially all of the Group's revenue from continuing operations from external customers and non-current assets are located in Hong Kong, the directors consider the presentation of geographical information unnecessary.

Information about major customers

Revenue from continuing operations from customers of corresponding years contributing over 10% of total revenue of the Group is as follows:

	Year ended 30 June 2013 *HK$*	Year ended 30 June 2012 *HK$*
Customer A[1]	**N/A[2]**	7,122,635
Customer B[1]	**6,924,569**	N/A[2]

1 Revenue from healthcare and pharmaceutical.

2 The corresponding revenue did not contribute over 10% or more to the Group's revenue from continuing operations in the respective year.

6. INVESTMENT AND OTHER INCOME

	Year ended 30 June 2013 *HK$*	Year ended 30 June 2012 *HK$* (restated)
Continuing operations		
Interest income on bank deposits	**4,561**	139,321
Other interest income	**2,493,414**	240,003
Dividend income from listed investments	**18,975**	–
Services income	**–**	540,000
Sundry income	**161,022**	606,261
	2,677,972	1,525,585

7. INCOME TAX (CREDIT)/EXPENSE

Income tax recognised in profit or loss

	Year ended 30 June 2013 *HK$*	Year ended 30 June 2012 *HK$* (restated)
Continuing operations		
Current tax:		
Hong Kong profits tax	**367,571**	395,437
Over provision in prior year:		
Hong Kong profits tax	**(56,823)**	–
Deferred tax:		
Current year	**(719,759)**	33,140
Total income tax recognised in profit or loss	**(409,011)**	428,577

Hong Kong profits tax is calculated at 16.5% of the estimated assessable profit for both years.

Subsidiaries operating in the People's Republic of China ("PRC") are subject to PRC Enterprise Income Tax at 25% for both years. Taxation arising in other jurisdictions is calculated at the rates prevailing in the relevant jurisdictions.

8. LOSS FOR THE YEAR FROM CONTINUING OPERATIONS

Loss for the year from continuing operations has been arrived at after charging:

	Year ended 30 June 2013 *HK$*	Year ended 30 June 2012 *HK$* (restated)
Employee benefits expense:		
Directors' emoluments	**2,299,248**	1,712,452
Other staff's salaries and allowances	**21,637,543**	26,090,058
Other staff's retirement benefits scheme contributions	**436,823**	801,693
Other staff's welfare	**135,337**	154,377
Total employee benefits expense	**24,508,951**	28,758,580
Auditors' remuneration	**430,000**	480,000
Depreciation of property, plant and equipment	**1,623,217**	2,155,497
Impairment losses recognised on trade and other receivables (included in "other operating expenses")	**–**	783,768
Operating lease rentals in respect of rented premises	**5,059,510**	3,875,473
Write-off of property, plant and equipment (included in "other operating expenses")	**–**	1,347,036
Write-off of inventories (included in "cost of sales and services provided")	**1,186,641**	465,205

9. DISCONTINUED OPERATION

Disposal of property investment operation

During the Year, the Company entered into a sale agreement to dispose of Million Worldwide Investment Limited and its subsidiaries (collectively, the "Million Worldwide Group"), which carried out all of the Group's property investment operation. The disposal was completed on 10 December 2012, on which date control of the property investment operation passed to the acquirer.

The combined results of the property investment operation included in the profit for the year are set out below.

Profit for the year from discontinued operation

	Year ended 30 June 2013 *HK$*	Year ended 30 June 2012 *HK$*
Revenue	**2,520,283**	5,993,129
Cost of services provided	**(148,386)**	(373,353)
Gross profit	**2,371,897**	5,619,776
Investment and other income	**40,585**	89,811
Administrative expenses	**(1,327,539)**	(5,068,536)
Other operating expenses	**(568,487)**	(821,957)
Loss arising on change in fair value of held-for-trading investments	**–**	(8,074,960)
Gain arising on change in fair value of investment properties	**–**	21,865,750
Profit before tax	**516,456**	13,609,884
Attributable income tax expense	**(120,791)**	(509,438)
	395,665	13,100,446
Gain on disposal of operation	**22,506,261**	–
Profit for the year from discontinued operation (attributable to owners of the Company)	**22,901,926**	13,100,446

Profit for the year from discontinued operation has been arrived at after charging/(crediting):

	Year ended 30 June 2013 *HK$*	Year ended 30 June 2012 *HK$*
Gross rental income from investment properties	**(2,520,283)**	(5,993,129)
Less: direct operating expenses	**148,386**	373,353
	(2,371,897)	(5,619,776)
Employee benefits expense:		
Other staff's salaries and allowances	**417,600**	2,336,898
Other staff's retirement benefits scheme contributions	**19,440**	60,433
Other staff's welfare	**4,451**	31,458
	441,491	2,428,789
Depreciation of property, plant and equipment	**45,402**	82,173
Operating lease rentals in respect of rented premises	**100,000**	626,475

10. DIVIDEND

No dividend has been paid or declared by the Company for the Year (2012: Nil).

11. EARNINGS/(LOSS) PER SHARE

From continuing and discontinued operations

The calculation of the basic and diluted earnings/(loss) per share attributable to owners of the Company is based on the following data:

	Year ended 30 June 2013 ***HK$***	Year ended 30 June 2012 *HK$*
Earnings/(loss)		
Earnings/(loss) for the purpose of basic and diluted earnings/(loss) per share (profit/(loss) for the year attributable to owners of the Company)	**11,682,665**	(16,181,273)

	Year ended 30 June 2013 ***Number of shares***	Year ended 30 June 2012 *Number of shares*
Number of shares		
Weighted average number of ordinary shares for the purpose of basic and diluted earnings/(loss) per share	**2,673,461,242**	1,220,686,649

The computation of diluted earnings per share for the Year does not assume the conversion of the Company's outstanding convertible bonds since their exercise would result in an increase in earnings per share. In addition, the computation of the diluted earnings/(loss) per share for the years ended 30 June 2013 and 2012 does not assume the exercise of the Company's outstanding share options as the exercise price of those options are higher than the average market prices of the Company's shares during the years.

From continuing operations

The calculation of the basic and diluted loss per share from continuing operations attributable to owners of the Company is based on the following data:

	Year ended 30 June 2013 *HK$*	Year ended 30 June 2012 *HK$*
Earnings/(loss)		
Profit/(loss) for the year attributable to owners of the Company	**11,682,665**	(16,181,273)
Less:		
Profit for the year from discontinued operation	**(22,901,926)**	(13,100,446)
Loss for the purpose of basic and diluted loss per share from continuing operations	**(11,219,261)**	(29,281,719)

The denominators used are the same as those detailed above for both basic and diluted loss per share.

The computation of diluted loss per share for continuing operations for the Year does not assume the conversion of the Company's outstanding convertible bonds since their exercise would result in a decrease in loss per share. In addition, the computation of the diluted loss per share for continuing operations for the years ended 30 June 2013 and 2012 does not assume the exercise of the Company's outstanding share options as the exercise price of those options are higher than the average market prices of the Company's shares during the years.

From discontinued operation

Basic and diluted earnings per share for the discontinued operation is HK0.9 cent per share (2012: HK1.1 cents per share), based on the profit for the Year from the discontinued operation of HK$22,901,926 (2012: HK$13,100,446) and the denominators detailed above for both basic and diluted earnings per share.

12. TRADE AND OTHER RECEIVABLES

	As at 30 June 2013 HK$	As at 30 June 2012 HK$
Trade receivables	**5,029,881**	6,890,681
Receivables arising from dealing in listed securities	**3,362,979**	839,565
Deposits paid in respect of acquisition of Sino-Mongolia Fluorspar Mining Co., Ltd. ("Target Company")	**32,500,000**	23,000,000
Other deposits paid	**2,289,980**	2,873,724
Prepayments	**7,476,851**	791,169
Loan receivables	**21,324,918**	12,000,000
Other receivables	**1,198,063**	412,833
	73,182,672	46,807,972

The following is an aged analysis of trade receivables, presented based on the invoice date:

	As at 30 June 2013 HK$	As at 30 June 2012 HK$
0 – 30 days	**3,027,360**	3,936,169
31 – 60 days	**958,421**	1,544,481
61 – 90 days	**222,351**	460,633
Over 90 days	**821,749**	949,398
	5,029,881	6,890,681

The Group grants a credit period ranging from 30 to 60 days to its customers. No interest is charged on overdue trade receivables. The management closely monitors the credit quality of trade and other receivables and considers the trade and other receivables that are neither past due nor impaired to be of a good credit quality. As at 30 June 2013, 55% (2012: 71%) of the trade receivables are neither past due nor impaired relate to a number of independent customers that have a good track record with the Group.

Trade receivables disclosed above include amounts (see below for aged analysis) which are past due at the end of the reporting period for which the Group has not recognised an allowance for doubtful debts because there has not been a significant change in the credit quality and the amounts are still considered recoverable.

Age of receivables that are past due but not impaired

	As at 30 June 2013 HK$	As at 30 June 2012 HK$
Up to 90 days	**872,752**	924,805
91 – 180 days	**633,475**	517,420
Over 180 days	**740,617**	542,379
	2,246,844	1,984,604

In determining the recoverability of a trade receivable, the Group considers any change in the credit quality of the trade receivable from the date credit was initially granted up to the end of the reporting period. The concentration of credit risk is limited due to the customer base being large and unrelated.

13. TRADE AND OTHER PAYABLES

	As at 30 June 2013 HK$	As at 30 June 2012 HK$
Trade payables	**2,124,695**	4,385,135
Other payables and accruals	**4,002,831**	3,359,115
Rental deposits received	**–**	1,210,754
	6,127,526	8,955,004

The following is an aged analysis of trade payables based on the invoice date:

	As at 30 June 2013 HK$	As at 30 June 2012 HK$
0 – 30 days	**1,289,141**	2,789,016
31 – 60 days	**393,093**	489,700
61 – 90 days	**17,455**	638,424
Over 90 days	**425,006**	467,995
	2,124,695	4,385,135

The average credit period on purchases of certain goods is 30 days. The Group has financial risk management policies in place to ensure that all payables are paid within the credit timeframe.

14. EVENTS AFTER THE REPORTING PERIOD

Acquisition of Sino-Mongolia Fluorspar Mining Co., Ltd.

On 15 May 2012, the Company announced that Huge Discovery Limited (an indirect wholly-owned subsidiary of the Company) (the "Purchaser") and Ms. Chen Yejun and Mr. Huang Tianhua (collectively, the "Vendors") entered into an acquisition agreement dated 7 May 2012 (as amended pursuant to deeds of variation dated 13 September 2012, 30 October 2012, 31 December 2012, 30 April 2013 and 7 May 2013), pursuant to which, among other things, the Purchaser has conditionally agreed to purchase, and the Vendors have conditionally agreed to sell, the entire equity interest in the Target Company and related shareholder loan, at a cash consideration of HK$148,000,000 (subject to adjustments). The aforesaid acquisition constituted a major transaction on the part of the Company under the GEM Listing Rules, and completion took place on 31 July 2013.

Following completion, the Target Company will become an indirect wholly-owned subsidiary of the Company, and the financial result and position of the Target Company and its subsidiary (collectively referred to as the "Target Group") will be consolidated into the consolidated financial statements of the Group. As at the date of this announcement, the management of the Group is still in the midst of determining the financial effect of the acquisition.

15. COMPARATIVE FIGURES

As a result of the discontinued operation as set out in note 9 of this announcement, certain comparative figures have been adjusted to conform to current year's presentation and to provide comparative amounts in respect of items disclosed for the first time in the current year.

BUSINESS REVIEW

The Group's major business includes the manufacturing and sale of pharmaceutical products, provision of advertising and public relations services and investment holding. Despite the fluctuating global economy during the Year, the Group reached the target performances in its major business areas.

Advertising and Public Relations Business

As Hong Kong is the world's leading financial centre, and with the more dynamic growth of the Asian economies, demand for financial services is blooming and the public relations industry is growing concurrently. Benefited from its valuable services provided to its customers and the good relationship with its customers, PR Asia Consultants Limited ("PR Asia") achieved to gain growing reputation and stronger foothold in the financial public relations industry in both Hong Kong and the PRC. For the Year, the Group's provisions of advertising and public relations services achieved a revenue of approximately HK$21,852,000, accounting for approximately 49.44% of the Group's total revenue. It also represented a drop of approximately 16.05% as compared with that of last year, which amounted to approximately HK$26,030,000. The decrease in revenue for the Year was mainly attributable to the decrease in the income from public relations projects provided to its customers.

PR Asia is a Hong Kong based public relations consultancy company focusing on financial communications. PR Asia provides strategic counselling services in corporate communications, media relations, investor relations, issue/crisis management, media training and event management to different clients including the companies listed in Hong Kong, private banks, quasi-government bodies and multi-national corporations with headquarters in Asia, Europe and America respectively.

PR Asia devises and implements effective business and marketing strategies from a communication perspective for its clients, with a view to enabling them to successfully achieve brand-building and establish an appropriate image to the targeted customer base. It also provides training, through simulating different scenarios of TV and print media interviews, to its clients for different kinds of interviews, media conferences and promotion events to ensure that the key messages are communicated from its clients to the public.

In addition, PR Asia could render assistance to its clients in reputation crisis management. The goal of PR Asia is to help its clients to manage crisis, balance the interests of different stakeholders and ensure corporate statements and undertakings are announced appropriately. PR Asia's income source is mainly divided into two major segments, namely retainer fees for services provided for a fixed period and project-based income.

With wider spectrum of clientele, the Group intends to continue to broaden the customer base and strengthen our market position.

Investments in held-for-trading securities

The Company had held-for-trading investments in the two listed securities in Hong Kong, the approximate market values amounted to approximately HK$13,577,000 as at 30 June 2013. During the Year, a gain of approximately HK$2,594,000 was recorded. The investments in the listed securities is one of the treasury policy of the Group for the use of certain surplus funds retained by the Group. Currently, the Group has no plan for further investments in the held-for-trading securities.

Manufacturing and Selling Pharmaceutical Products Business

Nowadays with the pursuit of healthy living and increases in Hong Kong's senior population, the demand for pharmaceutical products is growing rapidly. The Directors are of the view that the public's demand for medicine will continue to increase while a sustainable expansion in the pharmaceutical market is expected. The demand is triggered by the rapidly aging population and rising the standard of living in Hong Kong. It is also believed that the Department of Health is looking into adopting PIC/S (The Pharmaceutical Inspection Convention and Pharmaceutical Inspection Cooperation Scheme) standards to govern pharmaceutical manufacturing. PIC/S governance will imply higher Good Manufacturing Practice ("GMP") standards in a bid to bring the Hong Kong pharmaceutical environment on par with most western developed countries and some health authorities in the region, such as Singapore, Malaysia and Taiwan. Nevertheless, the Group will continue to review the development strategy in this business with respect to the new licensing requirement for the operation of a GMP certified factory in Hong Kong. For the Year, the Group's pharmaceutical business recorded a revenue of approximately HK$22,351,000 in the manufacturing and sales of pharmaceutical products, accounting for approximately 50.56% of the Group's total revenue. It also represented a drop of approximately 11.39% as compared with that of last year, which amounted to approximately HK$25,223,000. The decrease was attributable mainly to the slowdown of the economy experienced during the Year.

The pharmaceutical group comprises two sub-groups, namely:

– Vida Group: Manufacturing and sale of generic western medicines. The Vida Group's products are mainly branded generic medicines, such as remedies for cold and flu, cough, fever and skin infection. The Vida Group possesses a manufacturing licence and a wholesale poisons licence issued by the Department of Health of Hong Kong which is renewable annually, and is capable of producing medicines in different dosage forms including tablets, capsules, syrups, creams and ointments. Its major customers include private doctors, the Hospital Authority, over-the-counter retailers and medicine traders.

  Vida Group has taken steps to prepare for the imminent transition of the governance of Hong Kong pharmaceutical industry to PIC/S standards. Vida Group is evaluating the options either to upgrade its facilities (which may involve temporary production suspension) at the present site or in a suitable new location, or to outsource the production of some of its products to eligible third party producers.

- Kingston Group: Marketing and sale of health supplements, traditional Chinese medicines, sliming pills and beauty products. The company recently introduced a series of new health supplements, including DHA and colostrum pills, in a bid to expand the product offering. The Kingston Group sells its products via popular retail chains, internal sales platform and selected private clinics in Hong Kong. No specific licence/permit is required for the business of the Kingston Group.

Fluorite Processing and Trading Business

On 15 May 2012, a sales and purchase agreement was entered into between the Vendors and the Group to acquire a fluorite processing and trading business located in Outer Mongolia, at a consideration of HK$148,000,000 (subject to adjustment) in cash (the "Acquisition"). The completion of the Acquisition took place on 31 July 2013.

The Directors are of the view that the market demand for fluorite is significant and the prospect of the industry is promising. The Board believes the existing managements of the Group are able to identify and manage the local suppliers and explore potential customers in PRC and overseas. The Group expects that with the successful establishment of the customer base, the fluoride processing and trading business will provide a new and steady stream of revenue to the Group in the coming years. The Group could provide a full chain from upstream of fluorite processing to downstream of supplying fluorite particles of higher grade for customer consumption, which would enhance the competitive strength and further development in the industry.

OUTLOOK

Looking forward, in the view of the uncertainty over the global economic environment, the Group will maintain its diversified investment strategy in order to spread and lower the business risks, broaden the income source and maximise the shareholders' values, so as to secure the sustainable and stable growth across the Group's businesses. Following the completion of the Acquisition in July 2013, the management believes that the Acquisition will not only meet the Group's development strategy, but also provides an opportunity for the Group to explore a new stream of business in the processing and trading of fluorites and other natural resources.

The coming year is expected to be another year of complex external macroeconomic conditions. However, the management believes that opportunities coexist with challenges. With the intensive attention paid to the market changes, the Group will continue to modify its existing business strategies to cope with the changing business environment and make every effort to seek potential investment projects in line with the Group's future development so as to optimise its mix of investments in order to expand the value base for the shareholders.

FINANCIAL REVIEW

For the Year, the Group recorded revenue from continuing operations of approximately HK$44,203,000 (2012: HK$51,252,000), representing a decrease of 13.75% compared with the previous year. The gross profit from continuing operations for the Year was approximately HK$14,322,000 (2012: HK$19,540,000), representing a decrease of 26.70% compared with the previous year.

Basic earnings per share attributable to owners of the Company for the Year was HK0.4 cent (2012: basic loss per share of HK1.3 cents).

Profit attributable to owners of the Company for the Year was approximately HK$11,683,000 (2012: loss of approximately HK$16,181,000). The significant improvement was mainly due to gains arising on (i) change in fair value of held-for-trading investments; (ii) share of profits in associates; and (iii) disposal of discontinued operation.

The Board does not recommend the payment of final dividend for the Year.

Liquidity and Financial Resources

As at 30 June 2013, the Group held cash and cash equivalents of approximately HK$120,984,000 (2012: HK$32,847,000). Net current assets amounted to approximately HK$206,629,000 (2012: HK$103,314,000).

As at 30 June 2013, current ratio (defined as total current assets divided by total current liabilities) was approximately 34.72 times (2012: 12.54 times). Gearing ratio (expressed as the ratio of total liabilities over total assets) was approximately 0.01 (2012: 0.03).

The Group did not have any bank or other borrowings as at 30 June 2013 (2012: Nil).

Capital Structure

As at 30 June 2013, total equity attributable to owners of the Company was approximately HK$472,611,000 (2012: HK$313,138,000).

On 30 November 2012, a total of 1,000,000,000 new shares of HK$0.05 each was issued at the issue price of HK$0.05 per share, pursuant to the share placing agreement entered into between the Company and the placing agent on 9 May 2012.

On 18 March 2013, principal amount of HK$40,000,000 owed to the holder of the convertible note was converted to shares of the Company, resulting in the issue of 800,000,000 new shares of the Company of HK$0.05 each, at the conversion price of HK$0.05 per conversion share, pursuant to the convertible note placing agreement entered into between the Company and the placing agent on 9 May 2012.

On 2 May 2013, the remaining outstanding principle amount of HK$60,000,000 owed to the holder of the convertible note was fully converted to shares of the Company, resulting in the issue of 1,200,000,000 new shares of HK$0.05 each, at the conversion price of HK$0.05 per conversion share, pursuant to the convertible note placing agreement dated 9 May 2012.

Exchange Exposure

Most of the trading transactions, assets and liabilities of the Group were denominated in Hong Kong dollars. It is the Group's policy for its operating entities to operate in their corresponding local currencies to minimise currency risks. The Group had an insignificant exchange risk exposure since the principal businesses were conducted and recorded in Hong Kong dollars during the Year.

Significant Investments and Acquisitions

(a) Disposal of a subsidiary

In July 2012, the Group disposed of its entire equity interest in Core Medical Technology Limited to an independent third party at a cash consideration of HK$360,000.

(b) Acquisition of an investment property

In August 2012, the Group acquired an investment property situated in Hong Kong from an independent third party at a cash consideration of HK$6,600,000.

(c) Very substantial disposal and very substantial acquisition ("Transactions")

On 9 September 2012, the Company announced that a sale and purchase agreement (the "SP Agreement") dated 7 September 2012 was entered into between Chemosino International Limited ("CN BVI") (a directly wholly-owned subsidiary of the Company), as vendor, and Town Health Asset Management Limited ("TH Property Holding"), as purchaser. Pursuant to the SP Agreement, CN BVI has conditionally agreed to sell and TH Property Holding has conditionally agreed to acquire the entire issued share capital of Million Worldwide Investment Limited, a company wholly owned by CN BVI, at a consideration of HK$195,000,000 which will be satisfied by the allotment and issue of new shares in the capital of TH Property Holding (the "Consideration Shares") by TH Property Holding to CN BVI upon the completion of the aforesaid disposal. Immediately after the said completion, CN BVI would in turn own 25% of the issued share capital of TH Property Holding as enlarged by the issue of the Consideration Shares. The Transactions constitute a very substantial disposal and a very substantial acquisition on the part of the Company under the GEM Listing Rules, and was completed on 10 December 2012.

Pursuant to the SP Agreement, TH Property Holding had granted the first right ("First Right") in favour of the Group to subscribe for new shares of TH Property Holding if TH Property Holding proposed to raise fund by issue of new shares of TH Property Holding within a period of two years commencing from the completion date of the transactions at the aggregate consideration of a maximum of HK$100,000,000, which shall be effected by the giving of a funding notice by TH Property Holding to the Group.

On 15 May 2013, the Group received a funding notice from TH Property Holding indicating its intention to raise fund in the amount of HK$17,000,000 ("Subscription Consideration") by way of issue of 17 ordinary shares ("First Right Shares") of HK$1.00 each. On 16 May 2013, the Group issued an exercise notice to TH Property Holding to notify that it would exercise the First Right to subscribe for the First Right Shares at the Subscription Consideration stated in the funding notice and the completion of subscription took place on 16 May 2013. Immediately following the completion of the subscription, the Group's shareholdings in TH Property Holding was increased to approximately 26.39% by the Group.

Capital Commitment

As at 30 June 2013, the Group had no significant capital commitment.

Pledge of Assets

As at 30 June 2013, none of the assets of the Group were pledged as security for any banking facilities.

Employee Information

As at 30 June 2013, there were 86 staff members (2012: 109) employed by the Group.

The Group remunerates its employees mainly based on industry practices and their respective educational background, experience and performance. On top of the regular remuneration and discretionary bonus, share options may be granted to selected employees by reference to the Group's performance as well as individual's performance. In addition, each employee enjoys mandatory provident fund, medical allowance and other fringe benefits.

Contingent Liabilities

As at 30 June 2013, the Group had no significant contingent liabilities.

OTHER INFORMATION

Directors' and Chief Executive's Interests and Short Positions in Shares, Underlying Shares and Debentures

As at 30 June 2013, none of the Directors and chief executive of the Company had any interests or short positions in the shares or underlying shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (the "SFO")) as recorded in the register required to be kept by the Company pursuant to Section 352 of the SFO, or as otherwise notified to the Company and the Stock Exchange pursuant to Rules 5.46 to 5.67 of the GEM Listing Rules.

Substantial Shareholders' Interests and Short Positions in Shares and Underlying Shares

As at 30 June 2013, so far as is known to the Directors and the chief executive of the Company, the interests and short positions of the persons or corporations (other than the Directors and the chief executive of the Company) in the shares and underlying shares of the Company as recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO; or who was directly or indirectly, to be interested in 5% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of the Company or any other members of the Group, were as follows:

Long position in ordinary shares of HK$0.05 each of the Company

Name of Shareholders	Nature of interests	Number of shares held	Approximate percentage of shareholding
Tai Pu Mining International Co., Ltd *("Note")*	Beneficial owner	1,300,000,000	27.88%
Mr. Hu Zhixiong *("Note")*	Controlled entity	1,300,000,000	27.88%
Mr. Zhang Lijun	Personal	258,000,000	5.53%

Note: Tai Pu Mining International Co., Ltd is a company wholly and beneficially owned by Mr. Hu Zhixiong.

Save as disclosed above, as at 30 June 2013, so far as is known to the Directors and the chief executive of the Company, and based on the public records filed on the website of the Stock Exchange and records kept by the Company, no other person or corporation has interests or short positions in the shares or underlying shares of the Company as recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO; or, who was directly or indirectly, interested in 5% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of the Company or any other members of the Group.

Share Options

1. A share option scheme (the "Share Option Scheme") was adopted by the Company on 20 April 2004 for the purpose of providing incentives and rewards to eligible participants who contribute to the success of the Group's operations. The Board may, at its discretion, invite any employees, directors, advisers, consultants, licensors, distributors, suppliers, agents, customers, joint venture partners, strategic partners and services providers of and/or to any member of the Group whom the Board considers in its sole discretion, have contributed to the Group from time to time to take up options to subscribe for shares of the Company.

   As at 30 June 2013, there was no outstanding share options available to subscribe for shares of the Company under the Share Option Scheme. No share options was granted, exercised, cancelled or lapsed during the Year.

2. Pursuant to an agreement dated 8 August 2002 entered into between the Company and The Chinese University of Hong Kong (the "Chinese University") relating to the grant of a right of first refusal to the Company by the Chinese University in respect of certain technology and inventions, as amended and supplemented by agreements dated 31 October 2003 and 16 April 2004 (the "Right of First Refusal Agreement"), share options would be granted to the Chinese University or such persons as it might direct over the period of the term of such agreements of four years commencing from 18 June 2004.

   Details of the movements of the share options granted to the person directed by the Chinese University during the Year are as follows:

Date of grant	Exercise period	Exercise price per share	Outstanding as at 1 July 2011 and 30 June 2012	Lapsed during the year ended 30 June 2013	Outstanding as at 30 June 2013
		HK$			
27 June 2008 *(note)*	27 December 2008 to 26 June 2013	4.966	261,778	(261,778)	–

Note: The exercise price and outstanding number of options as at 1 July 2011 were retrospectively adjusted for the share consolidation which became effective on 6 August 2009, the share consolidation which became effective on 21 January 2010 and adjusted for the Open Offer which became effective on 18 April 2012.

Directors' Rights to Acquire Shares or Debentures

Save as disclosed in the sub-sections headed "Directors' and chief executive's interests and short positions in shares, underlying shares and debentures" and "Share options" respectively under the section headed "Other information" in this announcement, at no time during the Year was the Company or any of its subsidiaries, a party to any arrangement to enable the Directors to acquire benefits by means of the acquisition of shares in or debentures of the Company or any other body corporate.

Competing Interests

During the Year, none of the Directors or controlling shareholders of the Company (as defined in the GEM Listing Rules) or any of their respective associates had any interest in a business which competes or may compete with the business of the Group or had or might have any conflicts of interest with the Group.

Purchase, Sale or Redemption of the Company's Listed Securities

Neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company's listed securities during the Year.

Compliance with Code of Conduct for Securities Transactions by Directors

The Company has adopted the required standard of dealings as set out in Rules 5.48 to 5.67 of the GEM Listing Rules as a code of conduct of the Company regarding securities transactions by the Directors. The Company has made specific enquiry of all the Directors, and the Directors have complied with the required standard of dealings and the Company's code of conduct regarding securities transactions by the Directors throughout the Year.

Code on Corporate Governance Practices

The Company endeavours in maintaining high standard of corporate governance for the enhancement of shareholders' value. The Company has applied the principles of and complied with all the applicable code provisions and, where appropriate, the applicable recommended best practices of the Code on Corporate Governance Practices (the "CG Code") as set out in Appendix 15 to the GEM Listing Rules during the Year.

Remuneration Committee

The Company has established a remuneration committee (the "Remuneration Committee") with written terms of reference in compliance with the CG Code. The Remuneration Committee is mainly responsible for (i) making recommendation to the Board on policies and structure for all remuneration of Directors and senior management and on the establishment of a formal and transparent procedure for developing policy on such remuneration; (ii) determining the remuneration packages of individual executive Directors and senior management; and (iii) making recommendations to the Board on the remuneration of non-executive directors.

As at the date of this announcement, the Remuneration Committee comprises three independent non-executive Directors, namely Mr. Tam B Ray, Billy (committee chairman), Mr. Chi Chi Hung, Kenneth and Mr. Yan Shengxian.

Nomination Committee

The Company has established the nomination committee (the "Nomination Committee") with written terms of reference in compliance with the CG Code. On 29 August 2013, the Board resolved to adopt the board diversity policy (the "Board Diversity Policy") by the Nomination Committee. The Board Diversity Policy sets out the approach to diversity on the board of directors of the Company. In reviewing and assessing the composition of the Board, the Nomination Committee will consider the benefits of all aspects of diversity, which would include but not limited to gender, age, cultural and educational background, ethnicity, professional experience, skills, knowledge and length of service.

The principal responsibilities of the Nomination Committee include (i) formulating nomination policy; (ii) making recommendations to the Board on nomination and appointment of Directors and Board succession, developing selection procedures for nomination candidates; (iii) reviewing the size, structure, composition and diversity of the Board; (iv) assessing the independence of independent non-executive Directors; and (v) review the Board Diversity Policy and the measurable objectives that the Board has set for implementing the Board Diversity Policy.

As at the date of this announcement the Nomination Committee comprises three independent non-executive Directors, namely Mr. Tam B Ray, Billy (committee chairman), Mr. Chi Chi Hung, Kenneth and Mr. Yan Shengxian.

Audit Committee

The Company has established an audit committee (the "Audit Committee") with written terms of reference in compliance with the CG Code. The primary duties of the Audit Committee are to (i) review the Company's annual report and accounts, interim reports and quarterly reports; (ii) provide advice and comments thereon to the Board; and (iii) review and supervise the Group's financial reporting and internal control procedures.

The Audit Committee reviewed the Group's quarterly reports for the three months and nine months ended 30 September 2012 and 31 March 2013 respectively, interim report for the six months ended 31 December 2012 and the Group's audited annual results for the year ended 30 June 2013. The Audit Committee also made recommendations to the Board and the management in respect of the Group's financial reporting and internal control procedures.

As at the date of this announcement, the Audit Committee comprises three independent non-executive Directors, namely Mr. Chi Chi Hung, Kenneth (committee chairman), Mr. Tam B Ray, Billy and Mr. Yan Shengxian.

On behalf of the Board
China Natural Investment Company Limited
Cai Da
Chief Executive Officer

Hong Kong, 24 September 2013

As at the date of this announcement, the Board comprises (i) five executive Directors namely, Mr. Li Wai Hung, Mr. Cai Da, Mr. Chen Liang, Mr. Chan Yanhua and Ms. Xiong Yun Huan; and (ii) three independent non-executive Directors namely, Mr. Tam B Ray, Billy, Mr. Chi Chi Hung, Kenneth and Mr. Yan Shengxian.